{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T03:36:01Z","timestamp":1791776161354,"version":"4.3.4"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tumor cells compete with T cells for methionine by overexpressing SLC43A2 (solute carrier family 43 member 2), leading to T cell exhaustion. However, the correlation between SLC43A2 and immune infiltration or malignant features in acute myeloid leukemia (AML) has rarely been explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We obtained gene expression data and clinical information from 173 AML patients in The Cancer Genome Atlas (TCGA) database. Statistical analyses were performed using R (v4.0.5). Differential expression, immune infiltration, functional enrichment, and survival analyses were conducted using online databases, including GEPIA, GSCA Lite, Kaplan\u2013Meier Plotter, KEGG, and TIMER2.\n                      <jats:italic>In vitro<\/jats:italic>\n                      , we established SLC43A2-knockdown cell lines and validated SLC43A2 expression via PCR. Flow cytometry was employed to analyze cell viability, counts, apoptotic cell ratios, and immune cell infiltration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      SLC43A2 was highly expressed in AML and associated with poorer survival. Enrichment analysis revealed that SLC43A2 is involved in lymphocyte activation, leukocyte adhesion, and immune response regulatory signaling pathways. Immune infiltration results showed that SLC43A2 positively correlated with immune exhaustion markers (all p &amp;lt; 0.05) and negatively correlated with CD8+ T, NK, and B cell infiltration (all p &amp;lt; 0.05). We constructed an SPI1-hsa-miR-31-5p-SLC43A2 transcriptional network to support the role of SLC43A2.\n                      <jats:italic>In vitro<\/jats:italic>\n                      experiments have shown that SLC43A2 is negatively correlated with the infiltration level of immune cells and positively correlated with the expression levels of PDCD1 and CTLA4. Moreover, lower SLC43A2 expression was associated with enhanced T cell cytotoxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The SLC43A2 gene may serve as a diagnostic, prognostic, and potential immune-related biomarker for AML patients. Blocking SLC43A2-associated signaling pathways could provide novel insights into immunotherapy for AML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1655766","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:19:04Z","timestamp":1758773944000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["SLC43A2-mediated immune cell infiltration: a potential therapeutic target in acute myeloid leukemia"],"prefix":"10.3389","volume":"16","author":[{"given":"Mengnan","family":"Li","sequence":"first","affiliation":[{"name":"School of Medicine, Nankai University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Medicine, Nankai University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tianjin First Central Hospital, Affiliated Hospital of Nankai University, School of Medicine, Nankai University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jile","family":"Liu","sequence":"additional","affiliation":[{"name":"First Central Clinical College, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan","family":"Zhao","sequence":"additional","affiliation":[{"name":"First Central Clinical College, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyu","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tianjin First Central Hospital, Affiliated Hospital of Nankai University, School of Medicine, Nankai University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tianjin First Central Hospital, Affiliated Hospital of Nankai University, School of Medicine, Nankai University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tianjin First Central Hospital, Affiliated Hospital of Nankai University, School of Medicine, Nankai University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00213","article-title":"Targeting the immune microenvironment in acute myeloid leukemia: A focus on T cell immunity","volume":"8","author":"Lamble","year":"2018","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Sci (New York NY)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"New Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz0463","article-title":"Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia","volume":"12","author":"Vadakekolathu","year":"2020","journal-title":"Sci Trans Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Sci (New York NY)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.cmet.2020.01.006","article-title":"Methionine metabolism shapes T helper cell responses through regulation of epigenetic reprogramming","volume":"31","author":"Roy","year":"2020","journal-title":"Cell Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"112186","DOI":"10.1016\/j.celrep.2023.112186","article-title":"Accumulation of branched-chain amino acids reprograms glucose metabolism in CD8(+) T cells with enhanced effector function and anti-tumor response","volume":"42","author":"Yao","year":"2023","journal-title":"Cell Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The warburg effect: how does it benefit cancer cells","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1042\/BCJ20160822","article-title":"Amino acid homeostasis and signalling in mammalian cells and organisms","volume":"474","author":"Br\u00f6er","year":"2017","journal-title":"Biochem J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.tcb.2021.08.002","article-title":"Solute carrier transporters: emerging central players in tumour immunotherapy","volume":"32","author":"Chen","year":"2022","journal-title":"Trends Cell Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.911378","article-title":"Comprehensive analysis of SLC43A2 on the tumor immune microenvironment and prognosis of liver hepatocellular carcinoma","volume":"13","author":"Liao","year":"2022","journal-title":"Front Genet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41419-023-05860-7","article-title":"SLC43A2 and NF\u03baB signaling pathway regulate methionine\/cystine restriction-induced ferroptosis in esophageal squamous cell carcinoma via a feedback loop","volume":"14","author":"Peng","year":"2023","journal-title":"Cell Death Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2682-1","article-title":"Cancer SLC43A2 alters T cell methionine metabolism and histone methylation","volume":"585","author":"Bian","year":"2020","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","article-title":"KEGG: kyoto encyclopedia of genes and genomes","volume":"28","author":"Kanehisa","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/pro.3715","article-title":"Toward understanding the origin and evolution of cellular organisms","volume":"28","author":"Kanehisa","year":"2019","journal-title":"Protein Sci: Publ Protein Soc"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.10.003","article-title":"Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer","volume":"39","author":"Bindea","year":"2013","journal-title":"Immunity"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"New Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01718-7","article-title":"Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26984","article-title":"Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Garcia-Manero","year":"2023","journal-title":"Am J Hematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic Malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Sci (New York NY)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"New Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119171","article-title":"Genetic ablation of LAT1 inhibits growth of liver cancer cells and downregulates mTORC1 signaling","volume":"24","author":"Kim","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00577-5","article-title":"The cutting-edge progress of immune-checkpoint blockade in lung cancer","volume":"18","author":"Zhou","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov"},{"key":"B28","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.669474","article-title":"Differentiation and regulation of T(H) cells: A balancing act for cancer immunotherapy","volume":"12","author":"Basu","year":"2021","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J Clin Invest"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1655766\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:51:03Z","timestamp":1789728663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1655766\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2025.1655766"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1655766","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"article-number":"1655766"}}